ArticleInternational ophthalmology2026
Effect of optical coherence tomography biomarkers on treatment outcomes in patients with diabetic macular edema.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate pre-treatment optical coherence tomography (OCT) biomarkers in patients with diabetic macular edema (DME) and to assess changes in these parameters and their impact on visual prognosis one year after intravitreal (IV) anti-VEGF and steroid treatment.
methodsThis retrospective study included 250 eyes of 250 patients with DME. Best-corrected visual acuity (BCVA) and routine ophthalmologic examinations were evaluated at baseline and at 4, 6, and 12 months after treatment. Spectral-domain OCT biomarkers assessed were central macular thickness (CMT), serous retinal detachment (SRD), disorganization of retinal inner layers (DRIL), hyperreflective dots (HRD), integrity of the ellipsoid zone (EZ) and external limiting membrane (ELM), intraretinal cyst (IRC) size, vitreomacular adhesion (VMA), epiretinal membrane (ERM), and macular cube volume (MCV). Patients were classified according to letter gain as good (> 10 letters), moderate (5-10 letters), or poor (< 5 letters) responders. Statistical analyses included one-way ANOVA and Kruskal-Wallis tests with post-hoc multiple comparisons.
resultsBCVA improved significantly at 4, 6, and 12 months after treatment (p < 0.001). Mean CMT, IRC, HRD, and MCV values showed significant reductions at all follow-up visits (p < 0.001). The good responder group had significantly lower baseline BCVA and higher baseline CMT, IRC, and HRD values (p < 0.001). In contrast, the poor responder group showed a significantly higher baseline presence of DRIL (p < 0.001).
conclusionIV anti-VEGF and dexamethasone treatments provide significant anatomical and functional improvement in DME. High baseline CMT, HRD, and IRC values may indicate a favorable visual prognosis, whereas the presence of DRIL at baseline is associated with limited visual gain. Providing accurate prognostic information at treatment initiation may improve patient compliance.
Indexed as
Identifiers
41790319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.